ICON PLC (ICLR)

ICON plc is a clinical research organization (CRO) founded in Dublin, Ireland in 1990. It is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. Its mission is to improve patients' lives by accelerating the development of customers' drugs and devices. The company has grown organically and through acquisitions, most notably the July 2021 merger with PRA Health Sciences, valued at $12.0 billion. More recent acquisitions include Oncacare, an oncology research site network, and BioTel Research, a provider of medical imaging and cardiac safety monitoring services, both in 2023.

ICON's offering covers clinical development, functional outsourcing and laboratory services. Clinical development spans Phases I-IV, peri- and post-approval work, data solutions, and site and patient access services. Laboratory services include bioanalytical, biomarker, vaccine, GMP and central laboratory testing. Revenue comes from clinical trial management, consulting, contract staffing, data solutions and laboratory services, delivered through strategic partnerships, preferred provider, full-service, functional service provision and stand-alone models. Patient access offerings include the Accellacare site network and in-home services, the Oncacare oncology network, a pediatric site network, and six Phase I clinical research units in the United States and Europe. Proprietary technologies include ICONIK, Health Cloud, FIRECREST and One Search, supporting risk-based monitoring, site selection and decentralized trial solutions.

ICON serves a majority of the world's top pharmaceutical and biotech companies, and is increasingly targeting mid-tier biopharma firms and medical device companies. Its therapeutic expertise includes oncology, orphan and rare diseases, CNS, dermatology, infectious disease, women's health and vaccines. Its work on the Pfizer and BioNTech COVID-19 vaccine trial is a notable example. In 2023, about 40.4% of revenue came from the United States, 48.7% from Europe and 10.9% from the Rest of World. Its strategy rests on four pillars: patient access and engagement, career development and employer of choice, enduring customer partnerships, and healthcare intelligence and applied innovation.

At December 31, 2023, ICON had approximately 41,100 employees in 106 locations across 53 countries. Its principal executive office is at South County Park, Leopardstown, Dublin 18, Ireland. It reports in U.S. dollars and is exposed to currencies such as the pound sterling and the euro. It financed the PRA merger with senior secured term and revolving credit facilities and uses interest rate caps and a swap to manage rate exposure. Operations in Ukraine, Russia and Belarus have been curtailed and are subject to sanctions and export controls.